Timber Creek Capital Management LLC Has $4.08 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Timber Creek Capital Management LLC reduced its stake in AstraZeneca PLC (NASDAQ:AZN) by 1.5% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 62,275 shares of the company’s stock after selling 952 shares during the period. Timber Creek Capital Management LLC’s holdings in AstraZeneca were worth $4,080,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Creative Planning grew its holdings in AstraZeneca by 8.0% during the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after purchasing an additional 16,692 shares during the period. Swedbank AB boosted its position in shares of AstraZeneca by 1.3% during the third quarter. Swedbank AB now owns 2,705,757 shares of the company’s stock worth $210,806,000 after purchasing an additional 35,000 shares in the last quarter. Stratos Wealth Advisors LLC grew its holdings in shares of AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after buying an additional 133 shares during the period. OLD National Bancorp IN increased its position in shares of AstraZeneca by 49.4% in the 3rd quarter. OLD National Bancorp IN now owns 12,347 shares of the company’s stock valued at $962,000 after buying an additional 4,081 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC increased its position in shares of AstraZeneca by 268.9% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 60,624 shares of the company’s stock valued at $4,723,000 after buying an additional 44,189 shares in the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on AZN. UBS Group raised AstraZeneca from a “neutral” rating to a “buy” rating in a research note on Thursday, February 13th. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. Finally, Morgan Stanley assumed coverage on shares of AstraZeneca in a research note on Wednesday, February 12th. They issued an “overweight” rating on the stock. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, AstraZeneca has a consensus rating of “Buy” and an average target price of $89.75.

AstraZeneca Trading Up 1.7 %

NASDAQ AZN opened at $74.80 on Wednesday. AstraZeneca PLC has a 52 week low of $62.75 and a 52 week high of $87.68. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93. The stock’s 50 day moving average price is $68.32 and its two-hundred day moving average price is $73.29. The stock has a market capitalization of $231.95 billion, a price-to-earnings ratio of 33.10, a PEG ratio of 1.41 and a beta of 0.46.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.05 EPS for the quarter, missing analysts’ consensus estimates of $1.10 by ($0.05). AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. As a group, analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

AstraZeneca Increases Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Monday, March 24th. Stockholders of record on Friday, February 21st will be issued a $1.03 dividend. This is a boost from AstraZeneca’s previous semi-annual dividend of $0.49. The ex-dividend date of this dividend is Friday, February 21st. This represents a dividend yield of 2%. AstraZeneca’s dividend payout ratio (DPR) is presently 43.36%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.